AU2001234602A1 - Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor - Google Patents

Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor

Info

Publication number
AU2001234602A1
AU2001234602A1 AU2001234602A AU3460201A AU2001234602A1 AU 2001234602 A1 AU2001234602 A1 AU 2001234602A1 AU 2001234602 A AU2001234602 A AU 2001234602A AU 3460201 A AU3460201 A AU 3460201A AU 2001234602 A1 AU2001234602 A1 AU 2001234602A1
Authority
AU
Australia
Prior art keywords
malignant tumor
potassium channel
brain region
abnormal brain
channel agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234602A
Other languages
English (en)
Inventor
Keith L. Black
Nagendra S. Ningaraj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/491,500 external-priority patent/US7018979B1/en
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU2001234602A1 publication Critical patent/AU2001234602A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001234602A 2000-01-26 2001-01-26 Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor Abandoned AU2001234602A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09491500 2000-01-26
US09/491,500 US7018979B1 (en) 2000-01-26 2000-01-26 Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
US61585400A 2000-07-14 2000-07-14
US09615854 2000-07-14
PCT/US2001/002743 WO2001054771A2 (fr) 2000-01-26 2001-01-26 Procede utilisant des agonistes des canaux potassiques pour l'apport d'un medicament jusqu'a une region anormale du cerveau et/ou jusqu'a une tumeur maligne

Publications (1)

Publication Number Publication Date
AU2001234602A1 true AU2001234602A1 (en) 2001-08-07

Family

ID=27050462

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001234602A Abandoned AU2001234602A1 (en) 2000-01-26 2001-01-26 Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor
AU2001233052A Abandoned AU2001233052A1 (en) 2000-01-26 2001-01-26 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001233052A Abandoned AU2001233052A1 (en) 2000-01-26 2001-01-26 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor

Country Status (4)

Country Link
EP (1) EP1251840A2 (fr)
JP (2) JP2003523965A (fr)
AU (2) AU2001234602A1 (fr)
WO (2) WO2001054680A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6946484B2 (en) 2000-04-26 2005-09-20 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
GB0021487D0 (en) * 2000-09-01 2000-10-18 Pfizer Ltd Pharmaceutical
US7049334B2 (en) * 2001-09-14 2006-05-23 Carlsbad Technology, Inc. Enhancement of learning and memory and treatment of amnesia
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
JP2005527510A (ja) * 2002-03-06 2005-09-15 セレジー ファーマシューティカルズ インコーポレーティッド 癌の治療において一酸化窒素模倣体を使用するための製剤および方法
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
PT2438913T (pt) 2002-03-20 2020-05-27 Us Veterans Affairs Canal de catiões não seletivos em células neurais e compostos que bloqueiam o canal para utilização no tratamento de edema cerebral
US7166293B2 (en) * 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US7244756B2 (en) 2002-06-26 2007-07-17 Poseidon Pharmaceuticals A/S Benzimidazol-2-one derivatives and their use
DE10240735A1 (de) * 2002-08-29 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verwendung von Modulatoren der NO-Signalkaskade und pharmazeutische Zusammensetzung
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
JP2007505142A (ja) * 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
WO2005120493A1 (fr) 2004-06-10 2005-12-22 Tohoku University Promoteur de l'effet anticancereux
ATE487484T1 (de) 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
WO2006036278A2 (fr) 2004-09-18 2006-04-06 University Of Maryland, Baltimore Agents therapeutiques ciblant le canal ncca-atp et leurs methodes d'utilisation
US20090012067A1 (en) * 2005-02-14 2009-01-08 Luciano Rossetti Modulation of Hypothalamic Atp-Sensitive Potassium Channels
WO2006091587A2 (fr) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Utilisation de minoxidil sulfate comme medicament anti-tumoral
US7550478B2 (en) * 2005-06-23 2009-06-23 Merck & Co. Inc. Tyrosine kinase inhibitors
EP3103451A1 (fr) 2007-01-12 2016-12-14 University of Maryland, Baltimore Ciblage de canal ncca-atp destiné à protéger les organes après un épisode ischémique
EP2167107B1 (fr) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibiteurs de canaux ncca-atp pour thérapie
JP2011521908A (ja) * 2008-05-09 2011-07-28 デューク ユニバーシティ チオレドキシンが細胞における一酸化窒素放出を調節するという知見に基づく疾患の治療法
GB0921525D0 (en) 2009-12-08 2010-01-27 Isis Innovation Product and method
KR102282716B1 (ko) * 2020-02-07 2021-07-29 포항공과대학교 산학협력단 일산화질소 공여체를 포함하는 뇌-혈관 장벽 투과성을 증가시키는데 사용하기 위한 조성물 및 그의 용도
KR102490837B1 (ko) 2020-03-19 2023-01-19 포항공과대학교 산학협력단 뇌-혈관 장벽 투과성을 증가시키는 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336963C (fr) * 1988-07-18 1995-09-12 Gary James Grover Methode d'inhibition de la necrose des cellules du myocarde et de conservation de la fonction cardiaque pendant une ischemie myocardique et (ou) une perfusion repetee
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
EP0555681A1 (fr) * 1992-02-13 1993-08-18 E.R. SQUIBB &amp; SONS, INC. Utilisation d'une combinaison d'activateurs des canaux de potassium et de composés sulfhydryle pour la fabrication d'un médicament pour le traitement de l'ischémie et de l'infarction du myocarde
US5262419A (en) * 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
IT1282686B1 (it) * 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
WO2000023102A1 (fr) * 1998-10-19 2000-04-27 New York University Procede de regulation de la permeabilite de la barriere hemato-encephalique

Also Published As

Publication number Publication date
JP2004508279A (ja) 2004-03-18
EP1251840A2 (fr) 2002-10-30
WO2001054771A2 (fr) 2001-08-02
JP2003523965A (ja) 2003-08-12
AU2001233052A1 (en) 2001-08-07
WO2001054771A3 (fr) 2002-06-20
WO2001054680A3 (fr) 2002-06-27
WO2001054680A2 (fr) 2001-08-02

Similar Documents

Publication Publication Date Title
AU2001234602A1 (en) Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor
IL137105A0 (en) Method for administering aspb28-human insulin
AU2003267203A1 (en) Method for administering thermotherapy to prevent the growth of tumors
AU3953299A (en) Laser for skin treatment
AU2001281015A1 (en) Method and system for program guide delivery
AU2001234493A1 (en) Compounds and methods for prevention and treatment of her-2/neu associated malignancies
AU2001249978A1 (en) Shaped biocompatible radiation shield and method for making same
AU3206299A (en) Method and apparatus for combining injury-mediated therapy and drug delivery
AU2002231034A1 (en) Non-invasive method for treating postural instability
AU2001237997A1 (en) Method and system for event-centric user profiling and targeting
AU2002356587A1 (en) Method and device for producing hard packs for cigarettes
AU2001265839A1 (en) Use of potassium channel agonists for the treatment of cancer
AU2001292883A1 (en) Improved method and apparatus for securing eyeglasses while being worn
AU3784999A (en) Methods for treatment of pain
AU3028100A (en) Method and apparatus for masking cryptographic operations
AUPQ754300A0 (en) Apparatus for and method of lining passageways
AU4694900A (en) Systems and methods for targeting a breast lesion
AU2001283850A1 (en) Method for protecting human skin
AU7363000A (en) Method for reducing the risk of cancer
AU2002235153A1 (en) Medical guidewire and method for making
AU5302400A (en) Apparatus and method for advancing cooling catheter
AU4524501A (en) System and method for tuning to an in-band channel and for identification via return-path
HUP0101698A3 (en) Dental syringe, adaptor for syringe tip
AU2000224679A1 (en) System and method for on-line medical file administration
AU3770100A (en) Blade insertion apparatus for keratomes